Skip to main content
. 2014 Nov 27;14:886. doi: 10.1186/1471-2407-14-886

Figure 5.

Figure 5

Wnt5a , FZD 4, FZD5 and RHOU are significantly down-regulated in newly diagnosed AML patients’ bone marrow samples compared to normal or CR group. Expression levels of Wnt5a, FZD4, FZD5 and RHOU were determined by RT-PCR analysis of bone marrow samples from AML patients, either newly-diagnosed (AML-ND) or in complete remission (AML-CR), and healthy donors (CON) using SYBR Green PCR Master Mix. The Mann–Whitney test was used to compare differences between the two groups.